MedTrace Logo

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

NCT02837692 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2017-10-30

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in elderly non-Asian adults compared with weight- and gender-matched young healthy non-Asian adults and to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in healthy Japanese adults.

Conditions

  • Healthy

Interventions

DRUG

JNJ-42847922 10 milligram (mg)

JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.

DRUG

JNJ-42847922 20 mg

JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.

DRUG

JNJ-42847922 40 mg

JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.

DRUG

JNJ-42847922 60 or 80 mg

JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2017-09-07
Completion
2017-09-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837692 on ClinicalTrials.gov